MétaCan
Menu
Back to cohort
Record W4214697251 · doi:10.1111/liv.15207

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)

2022· article· en· W4214697251 on OpenAlexaff
César Jiménez, Meritxell Ventura‐Cots, Margarita Sala, Margalida Calafat, Montserrat Garcı́a-Retortillo, Isabel Cirera, Núria Cañete, Germán Soriano, María Poca, Macarena Simón‐Talero, José Altamirano, Michael R. Lucey, Guadalupe García–Tsao, Robert S. Brown, Robert F. Schwabe, Elizabeth C. Verna, Bernd Schnabl, Francisco Bosques‐Padilla, Philippe Mathurin, Juan Caballería, Alexandre Louvet, Debbie L. Shawcross, Juan G. Abraldeṣ, Joan Genescà, Ramón Bataller, Vı́ctor Vargas

Bibliographic record

VenueLiver International · 2022
Typearticle
Languageen
FieldMedicine
TopicAlcohol Consumption and Health Effects
Canadian institutionsUniversity of Alberta HospitalUniversity of Alberta
FundersNational Institute on Alcohol Abuse and AlcoholismNational Institute of Diabetes and Digestive and Kidney DiseasesInstituto de Salud Carlos IIINational Institutes of Health
KeywordsRifaximinMedicineInternal medicineAlcoholic hepatitisGastroenterologyIncidence (geometry)Alcoholic liver diseaseHepatologyLiver diseaseModel for End-Stage Liver DiseaseCohortAdverse effectLiver functionHepatic encephalopathyCohort studyCirrhosisAntibioticsLiver transplantation

Abstract

fetched live from OpenAlex

BACKGROUND & AIMS: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort. METHODS: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end-stage liver disease (MELD). We evaluated bacterial infections, liver-related complications, mortality and liver function tests after 90 days. RESULTS: Twenty-one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p = .049), with a lower incidence of acute-on-chronic liver failure (ACLF) linked to infections within the treatment group. Liver-related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p = .01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment. CONCLUSIONS: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.027
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.379
Teacher spread0.324 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations47
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueLiver InternationalSame topicAlcohol Consumption and Health EffectsFrench-language works237,207